Financials data is unavailable for this security.
View more
Year on year Shanghai Hile Bio-Technology Co Ltd 's revenues fell -19.76% from 299.99m to 240.72m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 121.61m to 62.87m, a -48.30% decrease.
| Gross margin | 48.68% |
|---|---|
| Net profit margin | 0.16% |
| Operating margin | -22.12% |
| Return on assets | 0.02% |
|---|---|
| Return on equity | 0.68% |
| Return on investment | 0.03% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Hile Bio-Technology Co Ltd fell by 19.46m. Cash Flow from Financing totalled 159.99m or 66.46% of revenues. In addition the company used 8.37m for operations while cash used for investing totalled 171.09m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.93 |
|---|---|
| Tangible book value per share | 1.55 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.15 |
|---|---|
| Quick ratio | 2.92 |
| Total debt/total equity | 0.0511 |
|---|---|
| Total debt/total capital | 0.0504 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -49.38% and -49.39%, respectively. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 0.16% |
|---|---|
| Div growth rate (5 year) | 23.47% |
| Payout ratio (TTM) | 226.26% |
| EPS growth(5 years) | 23.64 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -95.00 |
More ▼
